COPD trials in Chile

6 of 6 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 2Taking people
  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  Where

  Chile, Concepción, Santiago, Talca, Temuco, Viña del Mar

  Age

  40 years and over

  People

  987 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07082738
• Phase 3Taking people
  Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

  Where

  Chillan, Recoleta, Santiago, Temuco, Viña del Mar

  Age

  40 years to 80 years

  People

  942 worldwide

  Run by

  Sanofi

  See details and how to joinNCT07190222 · EU 2024-518213-25-00
• Phase 3Taking people
  Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

  Where

  Santiago, Talca, Valdivia, Viña del Mar

  Age

  40 years to 80 years

  People

  942 worldwide

  Run by

  Sanofi

  See details and how to joinNCT07190209 · EU 2024-518016-39-00
• Phase 3Taking people
  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

  Where

  Curicó

  Age

  40 years to 80 years

  People

  981 worldwide

  Run by

  GlaxoSmithKline

  See details and how to joinNCT06959095 · EU 2024-520418-22-00
• Phase 3Taking people
  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  Where

  Curicó, Quillota, Santiago, Talca, Temuco, Victoria, Viña del Mar, Vitacura

  Age

  40 years to 80 years

  People

  5,250 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06283966 · EU 2023-507407-59-00
• Phase 3Taking people
  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  Where

  Chile, Concepción, Curicó, Quillota, Santiago, Talca

  Age

  40 years to 80 years

  People

  990 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06883305 · EU 2024-517458-90-00